New hope for liver cancer: drug cocktail targets tumors after immunotherapy fails

NCT ID NCT06309485

Recruiting now Disease control Sponsor: Zhejiang Haichang Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Mar 25, 2026 · Last updated May 22, 2026 · Updated 10 times

Summary

This study tests a new drug called WGI-0301 combined with sorafenib in 60 adults with advanced liver cancer that cannot be removed by surgery. Participants must have already tried immunotherapy (PD-1/PD-L1 inhibitors). The goal is to find the safest dose and see if the combination shrinks tumors. This is a second-line treatment, meaning it is for people whose cancer did not respond to or stopped responding to first-line therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

China Pharmaceutical University, Shanghai Gobroad Cancer Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200131, China
Prince of Wales Hospital
NOT_YET_RECRUITING

Hong Kong, Hong Kong
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
West China Hospital Sichuan University
RECRUITING

Chengdu, China

Conditions

Explore the condition pages connected to this study.

ADVANCED HEPATOCELLULAR CARCINOMA (HCC)